Skip to Content

AstraZeneca PLC - Stock Quote AZN

Rating as of

Morningstar's AstraZeneca PLC Stock Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

AstraZeneca Posts Strong Q1 Buoyed by COVID Product Sales and Strong Underlying Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

AstraZeneca reported strong first-quarter results ahead of our expectations, and we plan to moderately increase our fair value estimate based on the solid performance. The strength of the firm’s portfolio and pipeline developments continue to reinforce our wide moat rating.

Read Full Analysis

AstraZeneca PLC's Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Contact
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 83,100

AstraZeneca PLC's Related News